Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer

References

• BrayF, FerlayJ, SoerjomataramI, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• MenderesG, BlackJ, SchwabCL, SantinAD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Rev Anticancer Ther. 2016;16(1):83–98. doi:10.1586/14737140.2016.112110826568261
   PubMed Web of Science ®Google Scholar
• ShenDW, PouliotLM, HallMD, GottesmanMM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706–721. doi:10.1124/pr.111.00563722659329
   PubMed Web of Science ®Google Scholar
• ZhuH, LuoH, ZhangW, et al. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016;10:1885–1895. doi:10.2147/DDDT.S106412
   PubMed Web of Science ®Google Scholar
• YehCB, SuCJ, HwangJM, ChouMC. Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells. Eur J Med Chem. 2010;45(9):3981–3985. doi:10.1016/j.ejmech.2010.05.05320691337
   PubMed Web of Science ®Google Scholar
• DengLP, DongJ, CaiH, WangW. Cantharidin as an antitumor agent: a retrospective review. Curr Med Chem. 2013;20(2):159–166. doi:10.2174/09298671380480671123210849
   PubMed Web of Science ®Google Scholar
• TaoR, SunWY, YuDH, et al. Sodium cantharidinate induces HepG2 cell apoptosis through LC3 autophagy pathway. Oncol Rep. 2017;38(2):1233–1239. doi:10.3892/or.2017.577928677738
   PubMed Web of Science ®Google Scholar
• HaleAJ, Ter SteegeE, den HertogJ. Recent advances in understanding the role of protein-tyrosine phosphatases in development and disease. Dev Biol. 2017;428(2):283–292. doi:10.1016/j.ydbio.2017.03.02328728679
   PubMed Web of Science ®Google Scholar
• LeeH, YiJS, LawanA, et al. Mining the function of protein tyrosine phosphatases in health and disease. Semin Cell Dev Biol. 2015;37:66–72. doi:10.1016/j.semcdb.2014.09.02125263013
   PubMed Web of Science ®Google Scholar
• ChenJ, ZhaoX, YuanY, JingJJ. The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers. Cancer Cell Int. 2020;20(1):238. doi:10.1186/s12935-020-01315-732536826
   PubMed Web of Science ®Google Scholar
• LiuH, WuY, ZhuS, et al. PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer. Cancer Lett. 2015;359(2):218–225. doi:10.1016/j.canlet.2015.01.02025617799
   PubMed Web of Science ®Google Scholar
• Kuban-JankowskaA, Gorska-PonikowskaM, SahuKK, et al. Docosahexaenoic acid inhibits PTP1B phosphatase and the viability of MCF-7 breast cancer cells. Nutrients. 2019;11(11):2554. doi:10.3390/nu11112554
   Web of Science ®Google Scholar
• LiZ, HuC, ZhenY, et al. Pristimerin inhibits glioma progression by targeting AGO2 and PTPN1 expression via miR-542-5p. Biosci Rep. 2019;39(5).
   Web of Science ®Google Scholar
• ChenY, TangJ, LuT, LiuF. CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma. Thorac Cancer. 2020;11(7):1848–1860. doi:10.1111/1759-7714.1346532395869
   PubMed Web of Science ®Google Scholar
• JinT, LiD, YangT, et al. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival. Oncol Rep. 2019;42(2):717–725. doi:10.3892/or.2019.718031173266
   PubMed Web of Science ®Google Scholar
• DasariS, TchounwouPB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.02525058905
   PubMed Web of Science ®Google Scholar
• FangX, ZhongG, WangY, et al. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer. Cell Death Dis. 2020;11(7):531. doi:10.1038/s41419-020-2735-232661236
   PubMed Web of Science ®Google Scholar
• XiaoZ, WangC, TanZ, et al. Clinical efficacy and safety of sodium cantharidinate plus chemotherapy in non-small-cell lung cancer: a systematic review and meta-analysis of 38 randomized controlled trials. J Clin Pharm Ther. 2019;44(1):23–38. doi:10.1111/jcpt.1276130229971
   PubMed Web of Science ®Google Scholar
• TaoR, WangZF, QiuW, et al. Role of S100A3 in human hepatocellular carcinoma and the anticancer effect of sodium cantharidinate. Exp Ther Med. 2017;13(6):2812–2818. doi:10.3892/etm.2017.429428588665
   PubMed Web of Science ®Google Scholar
• ZangGH, LiR, ZhouRS, et al. Effects of disodium cantharidinate on dendritic cells of patients with bladder carcinoma. Oncol Lett. 2018;15(2):2273–2277. doi:10.3892/ol.2017.758929434934
   PubMed Web of Science ®Google Scholar
• KostrzewaT, StyszkoJ, Gorska-PonikowskaM, et al. Inhibitors of protein tyrosine phosphatase ptp1b with anticancer potential. Anticancer Res. 2019;39(7):3379–3384. doi:10.21873/anticanres.1348131262859
   PubMed Web of Science ®Google Scholar
• YuM, LiuZ, LiuY, et al. PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p. FEBS J. 2019;286(6):1136–1153. doi:10.1111/febs.1472430548198
   PubMed Web of Science ®Google Scholar
• BartholomeuszC, Gonzalez-AnguloAM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):121–130. doi:10.1517/14728222.2011.64478822239433
   PubMed Web of Science ®Google Scholar
• AmiraniE, HallajzadehJ, AsemiZ, et al. Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy. Int J Biol Macromol. 2020;164:456–467. doi:10.1016/j.ijbiomac.2020.07.13732693135
   PubMed Web of Science ®Google Scholar
• KongDL, LiuY, WangJY, et al. Sodium cantharidinate suppresses human osteosarcoma MG63 cell proliferation and induces cell cycle arrest by inhibition of PI3K/AKT activation. Oncol Rep. 2019;41(2):1351–1358. doi:10.3892/or.2018.690630535442
   PubMed Web of Science ®Google Scholar
• HuangJ, JiangR, ChuX, et al. Overexpression of microRNA-23a-5p induces myocardial infarction by promoting cardiomyocyte apoptosis through inhibited of PI3K/AKT signalling pathway. Cell Biochem Funct. 2020;38(8):1047–1055. doi:10.1002/cbf.353632519337
   PubMed Web of Science ®Google Scholar
• ZhangY, LiuJL, WangJ. KRAS gene silencing inhibits the activation of PI3K-Akt-mTOR signaling pathway to regulate breast cancer cell epithelial-mesenchymal transition, proliferation and apoptosis. Eur Rev Med Pharmacol Sci. 2020;24(6):3085–3096. doi:10.26355/eurrev_202003_2067332271426
   PubMed Web of Science ®Google Scholar